Treatment of vasculoproliferative conditions
AssigneeUCL Business PLC
InventorsJohn Greenwood, Stephen Moss, Xiaomeng Wang
Life of this patent
Estimating the term…
Abstract
This invention relates to the field of molecular physiology. Specifically, this invention relates to the prevention and/or treatment of vasculoproliferative conditions, especially those of the eye and in the treatment of tumours that exhibit vascular proliferation. Levels of leucine-rich alpha-2-glycoprotein (Lrg1) have been demonstrated to be increased in patients suffering from such conditions and animal models of such conditions. Antagonists of Lrg1 can be used to prevent and/or treat vasculoproliferative conditions.
Claims21
1-27. (canceled)
A method of treating a vasculoproliferative condition comprising administering to a patient in need thereof an effective amount of an antagonist of Lrg1.
A method of identifying antagonists of Lrg1 comprising:
- (a) providing a candidate antagonist, and
- (b) determining whether or not said candidate antagonist blocks the function or activity of Lrg1;
- wherein said candidate antagonist is identified as an antagonist of Lrg1 if blocking of the function or activity of Lrg1 is observed.
A monoclonal antibody which specifically recognises an epitope within amino acids L1-24 (SEQ ID NO:
- 3), L169-192 (SEQ ID NO:
- 4) or L227-252 (SEQ ID NO:
- 5) and which blocks:
- (a) Lrg1 activity;
- or
- (b) the interaction between:
- (i) ALK1 and Lrg1;
- (ii) Lrg1 and TGFβ Receptor II (TGFβRII);
- and/or (iii) Lrg1 and TGFβ.
A method for determining what sites within Lrg1 can be targeted to block the function or activity of Lrg1, comprising:
- (a) providing peptide fragments of the Lrg1 protein;
- and
- (b) determining whether or not said each of said peptide fragments blocks the function or activity of Lrg1.
Dependencies are inferred from the claim text.